摘要
非小细胞肺癌(NSCLC)是我国最常见的恶性肿瘤,EGFR-TKI作为靶向药物治疗晚期NSCLC效果显著。但EGFR-TKIs相关性腹泻的发生会影响患者的生活质量,降低靶向治疗的依从性,耽误疾病的治疗。中医药在治疗EGFR-TKIs相关性腹泻方面具有一定的优势,甚至可以辅助靶向药物预防疾病复发与转移。文章对现有文献进行总结和提炼,概述中医药治疗EGFR-TKIs相关性腹泻的进展。
Non-small cell lung cancer (NSCLC) is the most common malignant tumor in China, and EGFR-TKI is effective as a targeted drug in the treatment of advanced NSCLC. However, the occurrence of EGFR-TKIs-associated diarrhea will affect the quality of life of patients, reduce the compliance of targeted therapy, and delay the treatment of the disease. Traditional Chinese medicine has certain advantages in the treatment of EGFR-TKIs-associated diarrhea, and can even assist targeted drugs to prevent disease recurrence and metastasis. This article summarizes and refines the existing lit-erature, and summarizes the progress of traditional Chinese medicine in the treatment of EGFR- TKIs-associated diarrhea.
出处
《中医学》
2023年第11期3317-3322,共6页
Traditional Chinese Medicine
